au-amc MCQ (SBA): Obesity and CVD risk pharmacotherapy

Instant feedback + full explanation. One question, done properly.

HardEndocrinologyObesity and CVD risk pharmacotherapyau-amcau-racp

A 36-year-old woman with BMI 38 kg/m² and well-controlled hypertension asks about pharmacological options for weight loss and cardiovascular risk reduction. She has no diabetes but a strong family history of myocardial infarction. Recent data show she qualifies for a GLP-1 receptor agonist approved for weight management and CVD risk reduction in people with obesity and established or high CVD risk. Which agent matches this description in current Australian practice?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

au-amc MCQ: Obesity and CVD risk pharmacotherapy — Answer & Explanatio